Publications by authors named "Hakim Hadana"
Article Synopsis
- * Aprocitentan, a dual ET receptor antagonist, was tested and found to reduce blood pressure (BP) more efficiently in low-renin rats compared to normal renin rats, demonstrating lasting effects.
- * When combined with RAS blockers, aprocitentan was more effective in lowering BP compared to spironolactone, and it did so without causing kidney damage, suggesting its potential as a safer hypertension treatment.
Aims: We compared the efficacy of macitentan, a novel dual endothelin A/endothelin B receptor antagonist, with that of another dual endothelin receptor antagonist, bosentan, in a rat model of non-vasoreactive pulmonary hypertension (PH) with particular emphasis on right ventricular (RV) remodeling.
Methods And Results: Unlike monocrotaline or hypoxic/sugen rats, bleomycin-treated rats presented a non-vasoreactive PH characterized by the absence of pulmonary dilatation to adenosine. We therefore chose the bleomycin rat model to compare the effects of the maximally effective doses of macitentan and bosentan on pulmonary vascular and RV remodeling.
Novel antibacterial drugs that are effective against infections caused by multidrug resistant pathogens are urgently needed. In a previous report, we have shown that tetrahydropyran-based inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) display potent antibacterial activity and exhibit no target-mediated cross-resistance with fluoroquinolones. During the course of our optimization program, lead compound 5 was deprioritized due to adverse findings in cardiovascular safety studies.
View Article and Find Full Text PDF